SOLD
Hilco is seeking offers to acquire certain assets of Fastform Research Limited (In Liquidation) (“FastForm” or the “Company”), namely stock and tooling, on behalf of the Joint Liquidators of the Company, Seamas Keating and Gary Digney of AAB Group Accountants Limited.
Founded in 2003, FastForm was an innovative life sciences business dedicated to transforming fracture management, musculoskeletal care, and diabetic foot ulcer treatment. Built on the Company’s proprietary PolyTrexX smart polymer technology and DermaWick breathable liner, FastForm developed advanced immobilisation and offloading solutions designed to improve patient care, streamline clinical workflows, and reduce overall procedure costs.
FastForm’s flagship products include the ankle-foot orthosis and the total contact offloading system, custom-mouldable devices combine the secure fit of a cast with the convenience and comfort of a splint, delivering state-of-the-art treatment for orthopaedic fractures, musculoskeletal injuries, and wound care. The Company’s products are proven to help optimise patient pathways, reduce the need for clinic visits, and support limb salvage.
This sale offers buyers the opportunity to acquire high-quality stock and specialist tooling linked to a clinically validated product range with clear market demand.
FastForm holds a defined inventory of finished goods and components that provides an immediate opportunity for a purchaser to acquire commercial-grade product with minimal delay. As of May 2025, the Company holds c. €89k worth of stock at cost, with c. €17.6k being finished (cost value), all boxed and ready for shipment, together with a range of raw materials and components such as resin and spacer fabric, which have a typical shelf life of around eighteen months. The stock is in good condition, has been maintained to commercial standards, and is currently stored with the Company’s contract manufacturing partner in Waterford, Ireland.
Alongside its inventory, FastForm has a suite of high-quality tooling located with its contract manufacturing partner in Waterford, Ireland. The upper extremity tools, which date back approximately 12-15 years, and the lower extremity tools, developed more recently within the last 3-5 years, have been well maintained and remain in good working condition. The tools retain a significant remaining life expectancy, with an estimated capacity of 100,000 to 250,000 units.
Please note that the intellectual property relating to FastForm is subject to a registered charge in favour of the secured creditor and does not form part of the assets being sold by the Joint Liquidators.
This sale is strictly limited to the available stock and tooling. Interested parties should therefore base any offers solely on these assets, with no expectation that rights in the intellectual property will transfer as part of the process.
Hilco is acting as exclusive agent to the Company and its Joint Liquidators in connection with the proposed sale of some or all of the Company’s assets. The Joint Liquidators acts as an agent of the Company and without personal liability.
All sales are made strictly on an “as is, where is” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company, its Joint Liquidators, or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and its Joint Liquidators.
